---
title: "19:39 ET
			
			
				Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270229505.md"
description: "The Ademi Firm is investigating VYNE Therapeutics Inc. for potential breaches of fiduciary duty in its transaction with Yarrow Bioscience. VYNE shareholders will own about 3% of the combined company, while Yarrow shareholders will own 97%. The transaction limits competing bids for VYNE, and insiders receive substantial benefits. The investigation focuses on whether VYNE's board is fulfilling its fiduciary duties to shareholders."
datetime: "2025-12-19T00:40:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270229505.md)
  - [en](https://longbridge.com/en/news/270229505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270229505.md)
---

# 19:39 ET
			
			
				Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

, /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience.

Click here to learn how to join our investigation and obtain additional information or contact us at \[email protected\] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, VYNE shareholders will receive the pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, and the pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company. VYNE insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for VYNE by imposing a significant penalty if VYNE accepts a competing bid. We are investigating the conduct of the VYNE board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP  
Guri Ademi  
Toll Free: (866) 264-3995  
Fax: (414) 482-8001

SOURCE Ademi LLP

### Related Stocks

- [VYNE.US](https://longbridge.com/en/quote/VYNE.US.md)

## Related News & Research

- [Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet](https://longbridge.com/en/news/287273372.md)
- [Hold Rating for VYNE Therapeutics Amid Strategic Shift and Clinical Uncertainty Following Yarrow Bioscience Merger](https://longbridge.com/en/news/270039432.md)
- [Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT](https://longbridge.com/en/news/286953224.md)
- [AVB Stock Alert: Halper Sadeh LLC is Investigating Whether AvalonBay Communities, Inc. is Obtaining a Fair Price for its Shareholders](https://longbridge.com/en/news/287213382.md)
- [India charity commissioner orders Tata Trusts to defer board meeting amid probe, document says](https://longbridge.com/en/news/286595568.md)